phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

In recent weeks, we’ve explored some of the dangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement?

Illegal drug trafficking by global criminal organizations is already a challenge for U.S. law enforcement, and the threat of fake, adulterated and addictive drugs, like counterfeit fentanyl, being imported would only increase if drug importation proposals move forward. Law enforcement agencies, including the U.S. Customs and Border Patrol, are already overburdened.

Of note, the U.S. Drug Enforcement Administration (DEA) has already warned about the threat of counterfeit prescription products making their way into the United States illegally via Canada and other countries. This threat continues to grow, particularly with counterfeit opioids, and proposed importation schemes are expected to lead to an even greater quantity of these products entering the United States.

Given the substantial amount of time and resources required of federal, state and local law enforcement to disrupt drug trafficking, opening our borders to drug importation schemes would only heighten the burden and undermine the ability of law enforcement to keep Americans safe. Criminals are waiting to take advantage of an open border system. Here are a few examples of how drug trafficking and importation proposals can impact law enforcement:

  • Disrupting just one designer drug distribution ring that produced synthetic opioids involved law enforcement from 45 states and joint operations in 4 other countries, including Australia, New Zealand, Canada and Barbados.
  • To stop the unlawful importation of at least 100 kilograms of illegal synthetic compounds (enough to produce about 260,000 retail packets of dried product) from China, five processing facilities were searched in addition to warehouses across all five boroughs of New York City. Over 2 million packets of eight synthetic drugs were seized.
  • Criminals actively look to skirt law enforcement by mislabeling products and the like. The DEA’s July 2016 Case Study warns that “fentanyls are traditionally mixed into or sold as heroin, oftentimes without the customer’s knowledge.” They report, “the current fentanyl crisis is multi-faceted and involves a global supply of fentanyl and related materials. Counterfeit pills containing fentanyls are smuggled into the United States from Mexico and Canada.”

fentanyl+pills+report - graphic v2 - smaller.png

With large-scale importation proposals, we can’t ignore the danger of overwhelming already overburdened law enforcement agencies with increased counterfeit products, including opioids.

Learn more about the dangers of drug importation here: PhRMA.org/Importation

Allyson Funk

Ally is a former senior director of public affairs at PhRMA.

Allyson Funk

Author Twitter

Author LinkedIn

More oversight needed of unapproved medicines that threaten patients’ health

August 1, 2024

What they are saying: Florida Drug Importation Program is Unfeasible and Dangerous

January 17, 2024

Florida’s importation plan puts patients in danger

January 5, 2024

Three things to know about the accelerated approval pathway

December 12, 2022

ICYMI: Antimicrobial resistance spotlighted as growing public health threat

July 6, 2022

Why drug importation is bad for Americans

May 12, 2022

PhRMA submits comments on FDA’s proposed rule on drug importation

March 10, 2020

Drug importation: An old idea that is still a bad idea

January 28, 2020

What they’re saying: Safety is top concern for recent drug importation proposal

August 8, 2019

ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals

August 1, 2019

PhRMA responds to Florida’s request for information on drug importation

June 26, 2019

PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients

May 8, 2019

Look at the facts. Drug importation is dangerous.

February 22, 2019

Why state drug importation pilot programs don’t work

February 8, 2019

ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation

October 9, 2018

Securely dispose of your unwanted medicines on National Take Back Day

April 28, 2018

The Washington Post retracts PhRMA claim in opioid story

October 18, 2017

PhRMA response to Washington Post and 60 Minutes stories

October 16, 2017

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

October 12, 2017

Protect your health: Important disaster preparedness tips for Harvey and Irma

September 6, 2017

PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis

August 2, 2017

Opportunities to build upon enhanced competition for medicines in the marketplace

July 27, 2017

A critical opportunity to prevent prescription drug abuse

June 2, 2017

Former law enforcement officials raise concerns with drug importation proposals

May 11, 2017

The risks of counterfeit imported medicines

April 20, 2017

Resources for understanding the dangers of drug importation

March 28, 2017

ICYMI: What the experts are saying about importation

March 23, 2017

Case Study: How one online pharmacy knowingly endangered U.S. consumers

March 2, 2017

Why drug importation threatens patient safety

February 28, 2017

Fact Check Friday: The truth about drug importation and patient safety

February 24, 2017

What you don’t know about importation from Canada

February 17, 2017

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients

February 13, 2017

How drug importation schemes could increase U.S. law enforcement burdens

Prescription Drug Safety

Importation

How drug importation schemes could increase U.S. law enforcement burdens

March 16, 2017

How drug importation schemes could increase U.S. law enforcement burdens

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list